A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Exelixis, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 253,204 shares of EXEL stock, worth $6.57 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
253,204
Previous 204,232 23.98%
Holding current value
$6.57 Million
Previous $4.85 Million 17.4%
% of portfolio
0.08%
Previous 0.07%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $996,090 - $1.16 Million
48,972 Added 23.98%
253,204 $5.69 Million
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $964,872 - $1.14 Million
47,837 Added 30.59%
204,232 $4.85 Million
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $155,694 - $195,163
8,088 Added 5.45%
156,395 $3.75 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $656,232 - $783,756
34,466 Added 30.28%
148,307 $3.24 Million
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $218,984 - $246,824
-12,052 Reduced 9.57%
113,841 $2.18 Million
Q1 2023

May 15, 2023

SELL
$16.3 - $19.41 $1.95 Million - $2.32 Million
-119,562 Reduced 48.71%
125,893 $2.44 Million
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $2.37 Million - $2.76 Million
158,579 Added 182.53%
245,455 $3.94 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $137,152 - $194,795
8,747 Added 11.2%
86,876 $1.36 Million
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $925,784 - $1.23 Million
53,084 Added 211.95%
78,129 $1.63 Million
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $65,105 - $86,667
3,823 Added 18.01%
25,045 $568,000
Q4 2021

Feb 14, 2022

SELL
$15.84 - $21.88 $149,006 - $205,825
-9,407 Reduced 30.71%
21,222 $388,000
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $499,252 - $647,497
30,629 New
30,629 $647,000
Q4 2020

Feb 16, 2021

SELL
$18.39 - $24.8 $619,117 - $834,916
-33,666 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$20.67 - $26.94 $71,022 - $92,565
-3,436 Reduced 9.26%
33,666 $823,000
Q2 2020

Aug 13, 2020

SELL
$16.46 - $27.42 $195,956 - $326,435
-11,905 Reduced 24.29%
37,102 $881,000
Q1 2020

May 15, 2020

SELL
$14.46 - $21.8 $822,687 - $1.24 Million
-56,894 Reduced 53.72%
49,007 $844,000
Q4 2019

Feb 14, 2020

SELL
$15.15 - $18.89 $7.01 Million - $8.74 Million
-462,929 Reduced 81.38%
105,901 $1.87 Million
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $6.99 Million - $8.95 Million
395,308 Added 227.81%
568,830 $10.1 Million
Q2 2019

Aug 14, 2019

BUY
$18.93 - $24.75 $291,484 - $381,100
15,398 Added 9.74%
173,522 $3.71 Million
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $648,015 - $818,615
33,062 Added 26.44%
158,124 $3.76 Million
Q4 2018

Feb 14, 2019

BUY
$13.65 - $21.8 $988,997 - $1.58 Million
72,454 Added 137.72%
125,062 $2.46 Million
Q3 2018

Nov 14, 2018

SELL
$15.87 - $22.4 $1.42 Million - $2 Million
-89,450 Reduced 62.97%
52,608 $932,000
Q2 2018

Aug 14, 2018

SELL
$18.56 - $22.45 $1.82 Million - $2.21 Million
-98,268 Reduced 40.89%
142,058 $3.06 Million
Q1 2018

May 15, 2018

SELL
$22.15 - $31.89 $4.3 Million - $6.19 Million
-193,983 Reduced 44.66%
240,326 $5.32 Million
Q4 2017

Feb 14, 2018

SELL
$24.23 - $30.93 $10.5 Million - $13.4 Million
-432,780 Reduced 49.91%
434,309 $13.2 Million
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $20.2 Million - $25.4 Million
867,089
867,089 $21 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.35B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.